Ribosomal protein L7a pseudogene 51 (RPL7AP51)

RPL7AP51, or ribosomal protein L7a pseudogene 51, is one of many processed pseudogenes derived from the parent RPL7A gene[7][2]. Pseudogenes like RPL7AP51 result from gene duplication or retrotransposition events and typically lack protein-coding potential due to accumulated disablements (such as premature stop codons or insertions/deletions)[2][7]. These pseudogenes are not translated into functional proteins, do not encode for enzymes, receptors, or transporters, and consequently do not serve as therapeutic or biomarker targets. Their presence in the genome can contribute to genetic diversity and have regulatory or evolutionary significance, but there is no evidence of a direct biological function, disease association, or relevance for drug development or clinical targeting for RPL7AP51[7][2]. The functional gene, RPL7A, encodes a component of the 60S large ribosomal subunit and is involved in protein synthesis[1][3][8]. In contrast, its pseudogenes (including RPL7AP51) are transcriptionally inactive and not therapeutically relevant[2][7]. Conclusion: RPL7AP51 is not a canonical pharmacological target and should not be considered a therapeutic or functional molecular target. The entry refers to a processed pseudogene, not an active gene or receptor[7][2].

Other names

RPL7A_17_1050RPL7AP51